Literature DB >> 24125181

Impact of PNPLA3 polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.

Masaya Sato1, Naoya Kato, Ryosuke Tateishi, Ryosuke Muroyama, Norie Kowatari, Wenwen Li, Kaku Goto, Motoyuki Otsuka, Shuichiro Shiina, Haruhiko Yoshida, Masao Omata, Kazuhiko Koike.   

Abstract

AIM: The PNPLA3 rs738409 C>G polymorphism (encoding for I148M) has recently been identified as a susceptibility factor for steatosis-mediated liver damage. We evaluated the influence of this polymorphism on hepatocarcinogenesis in patients with chronic hepatitis C (CHC) virus infection.
METHODS: We genotyped the rs738409 single nucleotide polymorphism in 358 hepatitis C-associated hepatocellular carcinoma (HCC) patients and correlated the age at onset of HCC and the interval between hepatitis C virus (HCV) infection and the development of HCC in patients with each genotype.
RESULTS: The frequencies of CC, CG and GG genotypes were 27.9% (100/358), 49.2% (176/358) and 22.9% (82/358), respectively, and were in Hardy-Weinberg equilibrium. The median age at onset of HCC for the GG genotype was significantly younger compared to for non-GG genotypes (67.81 vs 69.87 years, P < 0.001), and the median interval between HCV infection and the development of HCC was significantly shorter in patients with the GG genotype (39.96 vs 40.85 years, P = 0.008). PNPLA3 GG genotype was also associated with a higher aspartate aminotransferase level (69.5 vs 59.0 IU/L, P = 0.02), lower prothrombin time (73.0% vs 78.0%, P = 0.008) and a higher prevalence of histological steatosis (40.0% vs. 22.2%, P = 0.01) at the time of HCC onset.
CONCLUSION: The PNPLA3 genotype GG may be associated with accelerated hepatocarcinogenesis in CHC patients through increased steatosis in the liver.
© 2013 The Japan Society of Hepatology.

Entities:  

Keywords:  fibrosis; hepatocarcinogenesis; risk allele; rs738409; steatosis

Year:  2014        PMID: 24125181     DOI: 10.1111/hepr.12258

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  10 in total

Review 1.  Chronic hepatitis C virus infection and lipoprotein metabolism.

Authors:  Yoshio Aizawa; Nobuyoshi Seki; Tomohisa Nagano; Hiroshi Abe
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

Review 2.  PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease.

Authors:  Habeeb Salameh; Evan Raff; Angelika Erwin; Devanshi Seth; Hans Dieter Nischalke; Edmondo Falleti; Maria Antonella Burza; Julian Leathert; Stefano Romeo; Antonio Molinaro; Stefano Ginanni Corradini; Pierluigi Toniutto; Ulrich Spengler; Spengler Ulrich; Ann Daly; Christopher P Day; Yong-Fang Kuo; Ashwani K Singal
Journal:  Am J Gastroenterol       Date:  2015-05-12       Impact factor: 10.864

3.  Effect of PNPLA3 rs738409 variant (I148 M) on hepatic steatosis, necroinflammation, and fibrosis in Japanese patients with chronic hepatitis C.

Authors:  Kohichiroh Yasui; Takahisa Kawaguchi; Toshihide Shima; Hironori Mitsuyoshi; Kojiro Seki; Rei Sendo; Masayuki Mizuno; Yoshito Itoh; Fumihiko Matsuda; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2014-11-26       Impact factor: 7.527

Review 4.  Association of PNPLA3 I148M Variant With Chronic Viral Hepatitis, Autoimmune Liver Diseases and Outcomes of Liver Transplantation.

Authors:  Ning Geng; Yong-Ning Xin; Harry Hua-Xiang Xia; Man Jiang; Jian Wang; Yang Liu; Li-Zhen Chen; Shi-Ying Xuan
Journal:  Hepat Mon       Date:  2015-04-25       Impact factor: 0.660

5.  PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients.

Authors:  Kazunori Nakaoka; Senju Hashimoto; Naoto Kawabe; Yoshifumi Nitta; Michihito Murao; Takuji Nakano; Hiroaki Shimazaki; Toshiki Kan; Yuka Takagawa; Masashi Ohki; Takamitsu Kurashita; Tomoki Takamura; Toru Nishikawa; Naohiro Ichino; Keisuke Osakabe; Kentaro Yoshioka
Journal:  Springerplus       Date:  2015-02-13

6.  PNPLA3 polymorphism increases risk for and severity of chronic hepatitis C liver disease.

Authors:  Habeeb Salameh; Maen Masadeh; Muhannad Al Hanayneh; Vincent Petros; Matthew Maslonka; Arjun Nanda; Ashwani K Singal
Journal:  World J Hepatol       Date:  2016-12-18

Review 7.  Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection.

Authors:  Mohammad Irshad; Priyanka Gupta; Khushboo Irshad
Journal:  World J Hepatol       Date:  2017-12-28

8.  Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with chronic hepatitis C-related hepatocellular carcinoma.

Authors:  Hoang Hai; Akihiro Tamori; Le Thi Thanh Thuy; Kanako Yoshida; Atsushi Hagihara; Etsushi Kawamura; Sawako Uchida-Kobayashi; Hiroyasu Morikawa; Masaru Enomoto; Yoshiki Murakami; Norifumi Kawada
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

9.  Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients.

Authors:  Carla De Benedittis; Mattia Bellan; Martina Crevola; Elena Boin; Matteo Nazzareno Barbaglia; Venkata Ramana Mallela; Paolo Ravanini; Elisa Ceriani; Stefano Fangazio; Pier Paolo Sainaghi; Michela Emma Burlone; Rosalba Minisini; Mario Pirisi
Journal:  Gastroenterol Res Pract       Date:  2020-04-24       Impact factor: 2.260

10.  The impact of single-nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct-acting antiviral drugs for hepatitis C infection.

Authors:  Kosuke Matsumoto; Hisamitsu Miyaaki; Masanori Fukushima; Ryu Sasaki; Masafumi Haraguchi; Satoshi Miuma; Kazuhiko Nakao
Journal:  Biomed Rep       Date:  2021-12-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.